Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-23 | Amended | $27,289,180 | $13,894,590 | Equity Only | 06b | SEC link |
| 2024-12-31 | New | $13,394,590 | $13,394,590 | Equity Only | 06b | SEC link |
| 2023-10-20 | Amended | $38,399,997 | $12,399,999 | Equity Only | 06b | SEC link |
| 2022-07-28 | New | $25,999,998 | $25,999,998 | Equity Only | 06b | SEC link |
| 2020-12-16 | New | $15,441,157 | $15,441,157 | Equity Only | 06b | SEC link |
| 2018-07-25 | New | $660,000 | $660,000 | Debt Only | 06b | SEC link |
| Name | Role |
|---|---|
| Alexandra Cantley | Director |
| Isaac Ciechanover | Director |
| Anna French | Director |
| Christopher Guiffre | Executive |
| John Duncan Higgons | Director |
| Alon Lazarus | Director |
| Serge Messerlian | Director |
| Briggs Duncan Morrison | Director |
| Pini Orbach | Director |
| Victoria Richon | Director |
| Eric Shiozaki | Director |
| Katharine Yen | Director, Executive |